These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7794953)

  • 1. Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat, and lisinopril.
    Swaan PW; Stehouwer MC; Tukker JJ
    Biochim Biophys Acta; 1995 May; 1236(1):31-8. PubMed ID: 7794953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-transport relationship for the intestinal small-peptide carrier: is the carbonyl group of the peptide bond relevant for transport?
    Schoenmakers RG; Stehouwer MC; Tukker JJ
    Pharm Res; 1999 Jan; 16(1):62-8. PubMed ID: 9950280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability and in vitro absorption of captopril, enalapril and lisinopril across the rat intestine.
    Zhou XH; Li Wan Po A
    Biochem Pharmacol; 1994 Mar; 47(7):1121-6. PubMed ID: 8161340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Competitive inhibition of glycylsarcosine transport by enalapril in rabbit renal brush border membrane vesicles: interaction of ACE inhibitors with high-affinity H+/peptide symporter.
    Lin CJ; Akarawut W; Smith DE
    Pharm Res; 1999 May; 16(5):609-15. PubMed ID: 10350000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential renal handling of angiotensin-converting enzyme inhibitors enalaprilat and lisinopril in rats.
    Lin JH; Chen IW; Ulm EH; Duggan DE
    Drug Metab Dispos; 1988; 16(3):392-6. PubMed ID: 2900730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells.
    Thwaites DT; Cavet M; Hirst BH; Simmons NL
    Br J Pharmacol; 1995 Mar; 114(5):981-6. PubMed ID: 7780654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioimmunoassay for the quantitation of lisinopril and enalaprilat.
    Worland PJ; Jarrott B
    J Pharm Sci; 1986 May; 75(5):512-6. PubMed ID: 3016233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of angiotensin converting enzyme from sheep tissues by captopril, lisinopril and enalapril.
    Udupa EG; Rao NM
    Indian J Biochem Biophys; 1997 Dec; 34(6):524-8. PubMed ID: 9594434
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A calorimetric study of the binding of lisinopril, enalaprilat and captopril to angiotensin-converting enzyme.
    Andújar-Sánchez M; Cámara-Artigas A; Jara-Pérez V
    Biophys Chem; 2004 Oct; 111(2):183-9. PubMed ID: 15381315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinal absorption mechanism of dipeptide angiotensin converting enzyme inhibitors of the lysyl-proline type: lisinopril and SQ 29,852.
    Friedman DI; Amidon GL
    J Pharm Sci; 1989 Dec; 78(12):995-8. PubMed ID: 2559191
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic and metabolic aspects of enalapril action.
    Lant AF; McNabb RW; Noormohamed FH
    J Hypertens Suppl; 1984 Dec; 2(2):S37-42. PubMed ID: 6100875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The modified dipeptide, enalapril, an angiotensin-converting enzyme inhibitor, is transported by the rat liver organic anion transport protein.
    Pang KS; Wang PJ; Chung AY; Wolkoff AW
    Hepatology; 1998 Nov; 28(5):1341-6. PubMed ID: 9794920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noncompetitive inhibition of cephradine uptake by enalapril in rabbit intestinal brush-border membrane vesicles: an enalapril specific inhibitory binding site on the peptide carrier.
    Yuasa H; Fleisher D; Amidon GL
    J Pharmacol Exp Ther; 1994 Jun; 269(3):1107-11. PubMed ID: 8014854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of lisinopril, enalapril and enalaprilat in renal failure: effects of haemodialysis.
    Kelly JG; Doyle GD; Carmody M; Glover DR; Cooper WD
    Br J Clin Pharmacol; 1988 Dec; 26(6):781-6. PubMed ID: 2853960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the pharmacokinetics of fosinoprilat with enalaprilat and lisinopril in patients with congestive heart failure and chronic renal insufficiency.
    Greenbaum R; Zucchelli P; Caspi A; Nouriel H; Paz R; Sclarovsky S; O'Grady P; Yee KF; Liao WC; Mangold B
    Br J Clin Pharmacol; 2000 Jan; 49(1):23-31. PubMed ID: 10606834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid conversion of the new angiotensin converting enzyme inhibitor ramipril to its active metabolite in rats.
    Tabata S; Yamazaki H; Ohtake Y; Hayashi S
    Arzneimittelforschung; 1990 Aug; 40(8):865-7. PubMed ID: 2173610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compared properties of trandolapril, enalapril, and their diacid metabolites.
    Chevillard C; Jouquey S; Bree F; Mathieu MN; Stepniewski JP; Tillement JP; Hamon G; Corvol P
    J Cardiovasc Pharmacol; 1994; 23 Suppl 4():S11-5. PubMed ID: 7527095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carrier-mediated transport mechanism of foscarnet (trisodium phosphonoformate hexahydrate) in rat intestinal tissue.
    Swaan PW; Tukker JJ
    J Pharmacol Exp Ther; 1995 Jan; 272(1):242-7. PubMed ID: 7815338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age and the pharmacokinetics of angiotensin converting enzyme inhibitors enalapril and enalaprilat.
    Hockings N; Ajayi AA; Reid JL
    Br J Clin Pharmacol; 1986 Apr; 21(4):341-8. PubMed ID: 3011046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative pharmacokinetics of enalapril and lisinopril, alone and with hydralazine.
    McLean AJ; Drummer OH; Smith HJ; Froomes P; McNeil JJ
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():147-51. PubMed ID: 2550637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.